The treatment journey for multiple sclerosis (MS) patients in Europe is complicated and individualized, driven by the availability of a broad array of disease-modifying therapies (DMTs)—injectables, infusions, orals, and newcomers Ocrevus and Mavenclad—with more on the horizon. Current Treatment: Multiple Sclerosis (EU5) assesses in detail the current and near-term anticipated market dynamics and competitive landscape through comprehensive primary research with neurologists across the EU5, assessing DMT prescribing in key subpopulations, drivers of treatment selection, physicians’ insights on line of therapy/treatment sequencing, barriers to uptake, and other important dimensions.
Questions Answered
Product Description
Current Treatment: Physician Insights provides physician insights on treatment dynamics, prescribing behavior, and drivers of brand use so you can create specific messaging around these treatment dynamics in order to more effectively increase or defend your market position.
Markets covered: France, Germany, Italy, Spain, and the United Kingdom.
Primary research: Survey of 50 neurologists in France, Germany, Italy, Spain, and the United Kingdom.
Key companies: Sanofi Genzyme, Roche, Merck, Novartis, Biogen.
Key drugs: ABCRE therapies, Aubagio, Gilenya, Lemtrada, Mavenclad, Ocrevus, Plegridy, Tecfidera, Tysabri.
Key insights provided: